Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Cash and Equivalents of $128.45 million for fiscal year 2025.
SUPERNUS PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $128.45M | +85.3% |
| 2024 | $69.33M | -7.6% |
| 2023 | $75.05M | -19.4% |
| 2022 | $93.12M | -54.2% |
| 2021 | $203.43M | -29.5% |
| 2020 | $288.64M | +59.1% |
| 2019 | $181.38M | -5.7% |
| 2018 | $192.25M | +91.7% |
| 2017 | $100.30M | +51.1% |
| 2016 | $66.40M | +98.2% |
| 2015 | $33.50M | -8.0% |
| 2014 | $36.40M | +10.4% |
| 2013 | $32.98M | -18.2% |
| 2012 | $40.30M | -17.0% |
| 2011 | $48.54M | +104.5% |
| 2010 | $23.74M | -24.4% |
| 2009 | $31.41M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $151.37M | +377.9% | +4.6% |
| June 30, 2025 | $144.71M | +177.8% | +24.9% |
| March 31, 2025 | $115.85M | +82.7% | +67.1% |
| December 31, 2024 | $69.33M | -7.6% | +118.9% |
| September 30, 2024 | $31.67M | -66.7% | -39.2% |
| June 30, 2024 | $52.09M | +110.8% | -17.8% |
| March 31, 2024 | $63.40M | +8.5% | -15.5% |
| December 31, 2023 | $75.05M | -19.4% | -21.0% |
- SUPERNUS PHARMACEUTICALS, INC. showed an increase of +85.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, SUPERNUS PHARMACEUTICALS, INC.’s cash and equivalents has grown by 309.0% (from $31.41 million to $128.45 million).
- The most recent figure is from SUPERNUS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: